Type Size

    Fracture risk and zoledronic acid therapy in men with osteoporosis.

    In this multicenter, double-blind, placebo-controlled trial, the authors randomly assigned 1199 men (50 to 85 years of age) with primary or hypogonadism-associated osteoporosis to receive either an intravenous infusion of zoledronic acid (5 mg) or placebo at baseline and 12 months.  They found that the rate of new morphometric vertebral fracture was decreased by 67% with zoledronic acid (relative risk, 0.33; 95% confidence interval, 0.16 to 0.70; P=0.002) with no difference between groups in the incidence of death or serious adverse events.

    Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, et al

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Policies and Procedures for more details